EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer

Trial Profile

EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms EXTEND
  • Most Recent Events

    • 09 Aug 2017 Planned End Date changed from 30 Sep 2019 to 31 Dec 2018.
    • 09 Aug 2017 Planned primary completion date changed from 30 Sep 2019 to 31 Dec 2018.
    • 15 Jun 2017 Planned number of patients changed from 56 to 40.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top